ERBB2 and breast carcinoma: The limited efficacy of IO monotherapy in HR-positive/HER2-negative breast cancer has been hypothesized to be potentially related to lower PD-L1 expression, tumor-infiltrating lymphocytes (TILs) and tumor mutation burden (TMB) in this disease subset (9, 31–33).